29 Apr 2023 - 30 Apr 2023
08:55 AM - 01:50 PM
04th Knowledge Series for Genitourinary Cancers - Year In Review
Program Director: Dr Kumar Prabhash
04th Knowledge Series for Genitourinary Cancers - Year In Review Day 1|| 29th April,2023 || Day 2|| 30th April,2023
Day - 2 - 30 April 2023 - Session 1
Date : 30 Apr 2023
| First results from BladderPath: A randomised trial of MRI versus cystoscopic staging for newly diagnosed bladder cancer | 12:00 AM - 09:10 AM |
| NOVEL THERAPIES FOR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER. | 09:10 AM - 09:20 AM |
| COMPARISON OF ROBOT-ASSISTED AND OPEN RADICAL CYSTECTOMY IN RECOVERY OF PATIENT-REPORTED AND PERFORMANCE-RELATED MEASURES OF INDEPENDENCEA SECONDARY ANALYSIS OF A RANDOMIZED CLINICAL TRIAL | 09:20 AM - 09:30 AM |
| Bladder only versus bladder plus pelvic node chemoradiation for muscle invasive bladder cancer S.A. Patel, Y.Liu | 09:30 AM - 09:40 AM |
| Neoadjuvant Chemotherapy before Nephroureterectomy in High-Risk Upper Tract Urothelial Cancer: A Systematic Review and Meta-Analysis | 09:40 AM - 09:50 AM |
| Survival outcome compare radical nephroureperectomy vs endoscopy treatment in solitary kidney patients diagnosed with tract urothelial carcinoma | 09:50 AM - 10:00 AM |
| Effectiveness of Adjuvant Radiotherapy for High Recurrence Risk Patients with Upper Tract Urothelial Carcinoma | 10:00 AM - 10:10 AM |
| Moderator | 10:10 AM - 10:50 AM |
Day - 2 - 30 April 2023 - Session 2
Date : 30 Apr 2023
| LBA74 - Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC) | 10:55 AM - 11:05 AM |
| Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)1 | 11:05 AM - 11:15 AM |
| TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens. | 11:15 AM - 11:25 AM |
| ESMO 2022 EV-103 Cohort K: Enfortumab Vedotin ± Pembrolizumab in Untreated Cisplatin-Ineligible Patients With Locally Advanced/Metastatic Urothelial Carcinoma | 11:25 AM - 11:35 AM |
| FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression | 11:35 AM - 11:45 AM |
| Moderator | 11:45 AM - 12:15 PM |
Industry Symposium - Day 2 - 30 April 2023
Date : 30 Apr 2023
| Industry Symposium | 12:20 PM - 12:40 PM |
| QUIZ | 12:40 PM - 01:00 PM |
| First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study. | 01:00 PM - 01:20 PM |
| Differentially expressed messenger RNA/proteins can distinguish teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection tissue | 01:20 PM - 01:30 PM |
| Activity and tolerability of maintenance avelumab (AVE) immunotherapy after first-line platinum-based polychemotherapy in patients (pts) with locally after first-line platinum-based polychemotherapy in patients (pts) with locally advanced or metastatic sq | 01:30 PM - 01:45 PM |
Day - 1 - 29 April 2023 - Session 1
Date : 29 Apr 2023
| Welcome and Introduction | 08:55 AM - 09:00 AM |
| Outcomes of Grade Group 2 and 3 Prostate Cancer on Initial Versus Confirmatory Biopsy: Implications for Active Surveillance: ( M Perrera Eur Urol Focus 2022 Dec ) | 09:00 AM - 09:10 AM |
| PACE-A: An International Phase 3 Randomised Controlled Trial (RCT) Comparing Stereotactic Body Radiotherapy (SBRT) to Surgery for Localised Prostate Cancer (LPCa)—Primary Endpoint Analysis | 09:10 AM - 09:20 AM |
| Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis | 09:20 AM - 09:30 AM |
| Retzius Sparing Radical Prostatectomy Versus Robot- assisted Radical Prostatectomy: Which Technique Is More Beneficial for Prostate Cancer Patients (MASTER Study)? A Systematic Review and Meta- analysis | 09:30 AM - 09:40 AM |
| Radioisotope-guided Lymphadenectomy for Pelvic Lymph Node Staging in Patients With Intermediate- and High-risk Prostate Cancer (The Prospective SENTINELLE Study) | 09:40 AM - 09:50 AM |
| LBA9 - Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031) | 09:50 AM - 10:00 AM |
| Panel Discussion | 10:00 AM - 10:40 AM |
Day - 1 - 29 April 2023 - Session 2
Date : 29 Apr 2023
| Pooled outcomes of performing freehand transperineal prostate biopsy with the PrecisionPoint Transperineal Access System(BJUI Compass. 2022 Jun) | 10:45 AM - 10:55 AM |
| Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience | 10:55 AM - 11:05 AM |
| Superior Post-Treatment Biopsy Outcomes with High Dose SBRT Compared to High-Dose Conventionally Fractionated IMRT for Clinically Localized Prostate Cancer | 11:05 AM - 11:15 AM |
| FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP). (oral abstract 303) | 11:15 AM - 11:25 AM |
| Sequencing of Androgen Deprivation Therapy of Short Duration with Radiotherapy for Non-Metastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials | 11:25 AM - 11:35 AM |
| Impact of PSMA PET/CT on Prostate Cancer Salvage Radiotherapy Management: Results from the Prospective Randomized Phase 3 Trial [PSMA SRT NCT03582774] | 11:35 AM - 11:45 AM |
| Panel Discussion | 11:45 AM - 12:25 PM |
Day - 1 - 29 April 2023 - Session 3
Date : 29 Apr 2023
| Feasibility and safety of radical prostatectomy for oligo- metastatic prostate cancer: theTesting Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial | 12:30 PM - 12:40 PM |
| Efficiency and safety of Thalidomide in combination with ADT and Docetaxel | 12:40 PM - 12:50 PM |
| TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide Versus Placebo + ENZA as First-Line Treatment in Patients with mCRPC, | 12:50 PM - 01:05 PM |
| - Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study | 01:05 PM - 01:15 PM |
| Early results from a phase 1, multicenter trial of PSCA-specific GoCAR T cells (BPX601) in patients with metastatic castration-resistant prostate cancer (mCRPC). (poster 140) | 01:15 PM - 01:25 PM |
| 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in mCRPC Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603) - TheraP | 01:25 PM - 01:35 PM |
| NRG-GU011: A Phase II Double-Blinded, Placebo-Controlled Trial of Prostate Oligometastatic Radiotherapy with or Without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN) | 01:35 PM - 01:45 PM |
| Panel Discussion | 01:45 PM - 02:15 PM |
| Expert Comment | 02:15 PM - 02:20 PM |
Day - 1 - 29 April 2023 - Session 4
Date : 29 Apr 2023
| Renal cell carcinoma in renal transplant recipients : Is there a role of screening? | 03:05 PM - 03:15 PM |
| Development and Validation of a Nomogram Predicting Intraoperative Adverse Events During Robot-assisted Partial Nephrectomy: | 03:15 PM - 03:25 PM |
| Identifying patients for adjuvant therapy after nephrectomy U capitanio: lancet 2022 | 03:25 PM - 03:35 PM |
| Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with eckpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium | 03:35 PM - 03:45 PM |
| Bone Only Oligometastatic Renal Cell Carcinoma Patients Treated with Stereotactic Body Radiotherapy: A MULTI-Institutional Study | 03:45 PM - 03:55 PM |
| Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System | 03:55 PM - 04:05 PM |
| Panel Discussion | 04:05 PM - 04:45 PM |
| Expert Comment | 04:45 PM - 04:50 PM |
Day - 1 - 29 April 2023 - Session 5
Date : 29 Apr 2023
| LBA66 - IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection + LBA4 - Adjuvant nivolumab plus ipi | 05:20 PM - 05:30 PM |
| Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial (oral asbtract 603) | 05:30 PM - 05:40 PM |
| LBA 8-Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313) | 05:40 PM - 05:50 PM |
| 1462P - Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observatio | 05:50 PM - 06:00 PM |
| The grossing and reporting of post-immunotherapy nephrectomy specimens | 06:00 PM - 06:20 PM |
| Panel Discussion | 06:20 PM - 07:00 PM |
Industry Symposium - Day 1 - 29 April 2023
Date : 29 Apr 2023
Program Director:
Dr Kumar Prabhash
Contact Person
Garima Vashishtha
info@hcmpl.com
8178985238
Download